Fibrodysplasia ossificans progressiva (FOP): cross-border specialty drug access for international patients

Quick orientation

FOP is ultra-rare with an estimated prevalence of approximately 1 in 1.4 to 2 million people. Most cases are caused by recurrent ACVR1 R206H variants.

Typical age of onset. Typically presents in early childhood with painful soft-tissue swellings followed by heterotopic ossification.

Severity tiers. FOP causes progressive disability through ectopic bone formation in muscles, tendons, and connective tissue. Severity is uniformly disabling though the rate of progression varies.

Why specialty drugs for Fibrodysplasia ossificans progressiva (FOP) are hard to access internationally

Sohonos (palovarotene), approved by the FDA in 2023, is the first drug labeled to reduce heterotopic ossification in FOP. It is not yet registered in most international markets, and the rarity of the condition means local supply chains do not exist.

Treatments approved by the FDA

• Sohonos (palovarotene) — FDA approval: 2023. Mechanism: Retinoic acid receptor gamma agonist. Route: Oral once daily, flare-up dosing protocol. US WAC ballpark: Approximately USD 350,000 to 600,000 per year. Country pricing: Saudi Arabia · Bahrain · Lebanon.

Cross-border pathways used for Fibrodysplasia ossificans progressiva (FOP)

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Rare Pediatric Disease

What your physician needs to know

• Confirm ACVR1 pathogenic variant.
• Document flare-up history and current functional status.
• Sohonos carries premature epiphyseal closure risk in growing children; growth monitoring is essential.
• Mucocutaneous side effects are common and require monitoring.
• Coordinate with a clinical geneticist or FOP-experienced specialist where possible.

Common questions

Is Sohonos approved for children?

The label includes patients aged 8 years and older for females and 10 years and older for males, with specific growth-plate considerations.

Is it available outside the US?

International registration is in early stages.

What is the flare-up dosing protocol?

Higher doses are used during flare-ups and tapered. Your treating physician follows the label.

Are there side effects to watch for?

Mucocutaneous reactions, premature epiphyseal closure, and dry skin are common. Routine monitoring is required.

What documents are required?

Genetic confirmation, treating physician's prescription, and clinical summary.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Fibrodysplasia ossificans progressiva (FOP), our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Fibrodysplasia ossificans progressiva (FOP)

Reserved for you.